ID   A2780/TPT
AC   CVCL_4V45
DR   cancercelllines; CVCL_4V45
DR   Wikidata; Q54606611
RX   DOI=10.3969/j.issn.1004-7379.2004.03.003;
RX   PubMed=14693055;
RX   PubMed=15196431;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:63632; Topotecan.
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 10
//
RX   DOI=10.3969/j.issn.1004-7379.2004.03.003;
RA   Jia P., Li F., Wu M.-F., Liao G.-N., Lu Y.-P., Ma D.;
RT   "Establishment of topotecan-resistant ovarian cancer cell line.";
RL   Xian Dai Fu Chan Ke Jin Zhan 13:174-177(2004).
//
RX   PubMed=14693055;
RA   Jia P., Wu S.-B., Xu Q., Wu M.-F., Gao Q.-L., Liao G.-N., Lu Y.-P.,
RA   Ma D.;
RT   "Antisense oligonucleotide reverses topotecan-resistant ovarian cancer
RT   cells.";
RL   Ai Zheng 22:1296-1300(2003).
//
RX   PubMed=15196431; DOI=10.3760/j.issn:0253-3766.2004.03.003;
RA   Jia P., Wu S.-B., Li F., Xu Q., Wu M.-F., Liao G.-N., Lu Y.-P., Ma D.;
RT   "The mechanism of topotecan resistance in ovarian cancer cell line.";
RL   Zhonghua Zhong Liu Za Zhi 26:139-142(2004).
//